Ditchcarbon
  • Contact
  1. Organizations
  2. Shanghai Henlius Biotech
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated 7 days ago

Shanghai Henlius Biotech

Company website

Shanghai Henlius Biotech, also known as Henlius, is a prominent biopharmaceutical company headquartered in Shanghai, China. Founded in 2010, the company has rapidly established itself in the biotechnology industry, focusing on the research, development, and manufacturing of innovative monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. With a strong operational presence in both domestic and international markets, Henlius has achieved significant milestones, including the successful launch of its flagship products, which are distinguished by their high quality and affordability. The company is recognised for its commitment to advancing biopharmaceutical solutions, positioning itself as a key player in the global market. Henlius continues to expand its portfolio, aiming to enhance patient outcomes through cutting-edge therapies.

DitchCarbon Score

How does Shanghai Henlius Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

17

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Shanghai Henlius Biotech's score of 17 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.

12%

Let us know if this data was useful to you

Shanghai Henlius Biotech's reported carbon emissions

In 2023, Shanghai Henlius Biotech, headquartered in CN, reported total carbon emissions of approximately 21,973,000 kg CO2e. This figure includes 6,908,630 kg CO2e from Scope 1 emissions and 15,064,370 kg CO2e from Scope 2 emissions. Compared to 2022, where total emissions were about 21,163,930 kg CO2e, the company has shown a slight increase in emissions, primarily driven by growth in operations. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Notably, there are currently no specific reduction targets or climate pledges outlined by Shanghai Henlius Biotech, which may reflect a broader industry trend where many companies are still developing comprehensive climate strategies. Overall, while Shanghai Henlius Biotech has made strides in emissions reporting, the absence of reduction initiatives or targets suggests an opportunity for enhanced climate commitment in the future.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20202021
Scope 1
5,534,750
0,000,000
Scope 2
14,133,210
00,000,000
Scope 3
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Shanghai Henlius Biotech's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Shanghai Henlius Biotech is in CN, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Shanghai Henlius Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated about 20 hours ago

Guangzhou Gloria Biosciences Co., Ltd.

CN
Updated 8 minutes ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251005.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy